Protein Drugs: Global Markets and Manufacturing Technologies
October 08, 2008
Wellesley, Mass—According to a new technical market research report, PROTEIN DRUGS: GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES (BIO021C) from BCC Research, the global market for protein therapeutics was worth $86.8 billion in 2007 and an estimated $95.2 billion in 2008. This is expected to reach $160.1 billion in 2013 for a compound annual growth rate (CAGR) of 10.9%.
The market is broken down by type of protein drug and includes antibodies, cytokines, peptide hormones, vaccines, blood products, peptide antibiotics and enzymes. Of these, peptide hormones have the largest share of the market. Worth $26.1 billion in 2007, this segment is expected to increase to $27.9 billion in 2008 and $50.4 billion in 2013, for a CAGR of 12.6%.
The second largest share of the market belongs to cytokines, which generated $16.0 billion in 2007. This is expected to increase to $17.5 billion in 2008 and $26.8 billion in 2013, for a CAGR of 9.0%.
Blood products are the third largest market segment, worth $15.1 billion in 2007 and an estimated $15.9 billion in 2008. This should increase to $21.3 billion in 2013, for a CAGR of 6.1%.
Antibodies also have a significant share of the market. Worth $15.0 billion in 2007 and an estimated $18.1 billion in 2008. This segment should grow at a CAGR of 15.4% to reach $36.9 billion in 2013.
Although the drug development industry still focuses primarily on small molecules, in recent years protein and peptide therapeutics comprise a significant percent of the product line for most major pharmaceutical companies.
Protein drugs have received enormous attention from pharmaceutical companies due to a combination of their bioreactivity, specificity, safety and overall success rate. Yet there are still improvements to be made, especially with respect to their formulation and delivery method. Advances in protein drug delivery are certain to increase patient compliance and expand many drug markets.
Protein Drugs: Global Markets and Manufacturing Technologies ( BIO021C )
Publish Date: Oct 2008
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Cell Biology
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand
- Decentralized Clinical Trials Market to Reach $18.8 Billion by 2030 as Digital Health Infrastructure Reshapes Drug Development
Reports from Cell Biology
Recent News
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Long-Term Care and Home Healthcare Technology Market to Reach $64.8 Billion by 2030 as Aging Demographics and Remote Monitoring Reshape Care Delivery
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum